Conflicts of interest: Yao-Chi Chuang: consultant of Lipella and Allergan; Pradeep Tyagi: consultant of Lipella; Hsuan-Ying Huang, Naoki Yoshimura, Moya Wu: nothing to disclosure related to this study; Jonathan Kaufman: employee of Lipella; Michael B. Chancellor: consultant of Allergan and employee of Lipella.
Basic Science Paper
Article first published online: 21 SEP 2010
Copyright © 2010 Wiley-Liss, Inc.
Neurourology and Urodynamics
Volume 30, Issue 3, pages 421–427, March 2011
How to Cite
Chuang, Y.-C., Tyagi, P., Huang, H.-Y., Yoshimura, N., Wu, M., Kaufman, J. and Chancellor, M. B. (2011), Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol. Urodyn., 30: 421–427. doi: 10.1002/nau.20981
Lori Birder led the review process.
- Issue published online: 15 MAR 2011
- Article first published online: 21 SEP 2010
- Manuscript Accepted: 15 JUN 2010
- Manuscript Received: 6 APR 2010
- National Science Council Taiwan;
- Chang Gung Memorial Hospital CMRPG;
- Lipella Pharmaceutical, Inc.
Potent immunosuppressive effect of tacrolimus has encouraged its topical application for achieving local anti-inflammatory effect. However, its poor aqueous solubility presents challenges in formulating biocompatible instillations to justify the investigation of liposomes as vehicle for tacrolimus.
Adult female Sprague-Dawley rats (N = 52) divided into 4 groups were injected with cyclophosphamide (CYP) (200 mg/kg, ip) except for sham (saline injection, ip). Other three groups were instilled with either saline (1 cc, retained for 1 hr), liposome (LP- 1 cc) or liposomal encapsulated tacrolimus (LFK- 0.2 mg tacrolimus/1 ml LP). Baseline cystometrogram was performed on day 1 and day 3 prior to bladder harvest for histological staining (N = 24) in all groups except sham. In addition, 4-hr baseline urine on day 1 and day 3 was collected from all groups for urine PGE2 assay and bladder harvested for PGE2 and IL2 assay on day 3 (N = 28).
Rats treated with LFK demonstrated suppression of CYP induced inflammatory reaction with reduced EP4 staining and bladder overactivity (intercontraction interval 61.0% decrease in untreated animals) as well as normalized the several fold elevation of IL 2 and PGE2 levels in tissue and urine. CYP induced effects were not suppressed in rats left untreated with tacrolimus.
This is the first report of immunesuppression in bladder by intravesical delivery of tacrolimus using liposomes. LFK significantly inhibited CYP induced inflammatory cystitis through the modulation of IL2, PGE2, and EP4 function. These findings support investigation of local tacrolimus in cases of inflammatory cystitis refractory to conventional therapy. Neurourol. Urodynam. 30:421–427, 2011. © 2010 Wiley-Liss, Inc.